$MBIO
MUSTANG BIO, INC.

2020 Q4 Form 10-K Financial Statement

#000155837021003433 Filed on March 24, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2019 Q4 2019
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.410M $2.050M $9.570M
YoY Change 17.56% 22.02% 41.57%
% of Gross Profit
Research & Development $17.83M $13.87M $30.04M
YoY Change 28.55% 35.71% 1330.57%
% of Gross Profit
Depreciation & Amortization $460.0K $350.0K $1.300M
YoY Change 31.43% 12.9% 106.35%
% of Gross Profit
Operating Expenses $20.74M $15.92M $45.89M
YoY Change 30.28% 33.78% 46.96%
Operating Profit -$45.89M
YoY Change 46.96%
Interest Expense $130.0K -$290.0K -$500.0K
YoY Change -144.83% -323.08% -189.29%
% of Operating Profit
Other Income/Expense, Net -$504.0K
YoY Change -189.84%
Pretax Income -$20.61M -$16.21M -$46.39M
YoY Change 27.14% 37.72% 51.3%
Income Tax
% Of Pretax Income
Net Earnings -$20.61M -$16.21M -$46.39M
YoY Change 27.14% 37.72% 51.29%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$312.2K -$405.4K -$1.286M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $97.80M $61.40M $61.40M
YoY Change 59.28% 80.06% 80.06%
Cash & Equivalents $97.80M $61.41M $61.40M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $1.700M $1.600M $1.600M
YoY Change 6.25% 60.0% 60.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $99.53M $63.06M $63.10M
YoY Change 57.83% 79.54% 79.77%
LONG-TERM ASSETS
Property, Plant & Equipment $8.028M $7.936M $9.100M
YoY Change 1.16% 15.72% 31.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $250.0K $250.0K $1.300M
YoY Change 0.0% -7.75% 62.5%
Total Long-Term Assets $10.37M $10.38M $10.30M
YoY Change -0.15% 36.09% 33.77%
TOTAL ASSETS
Total Short-Term Assets $99.53M $63.06M $63.10M
Total Long-Term Assets $10.37M $10.38M $10.30M
Total Assets $109.9M $73.45M $73.40M
YoY Change 49.64% 71.79% 71.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.518M $1.877M $1.900M
YoY Change 87.43% -66.48% -66.07%
Accrued Expenses $5.100M $300.0K $3.500M
YoY Change 1600.0% 50.0% 1650.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $1.250M $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00 $1.300M $1.300M
YoY Change -100.0%
Total Short-Term Liabilities $9.515M $7.771M $7.800M
YoY Change 22.44% 38.35% 39.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $12.20M $12.20M
YoY Change -100.0%
Other Long-Term Liabilities $2.000M $1.800M $1.800M
YoY Change 11.11% 157.14% 157.14%
Total Long-Term Liabilities $2.000M $14.00M $14.00M
YoY Change -85.71% 1900.0% 1900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.515M $7.771M $7.800M
Total Long-Term Liabilities $2.000M $14.00M $14.00M
Total Liabilities $11.47M $21.79M $21.80M
YoY Change -47.39% 242.77% 240.63%
SHAREHOLDERS EQUITY
Retained Earnings -$185.5M -$125.5M
YoY Change 47.84% 58.67%
Common Stock $276.0M $172.2M
YoY Change 60.27% 51.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $98.44M $51.65M $51.70M
YoY Change
Total Liabilities & Shareholders Equity $109.9M $73.45M $73.40M
YoY Change 49.64% 71.79% 71.5%

Cashflow Statement

Concept 2020 Q4 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$20.61M -$16.21M -$46.39M
YoY Change 27.14% 37.72% 51.29%
Depreciation, Depletion And Amortization $460.0K $350.0K $1.300M
YoY Change 31.43% 12.9% 106.35%
Cash From Operating Activities -$9.480M -$9.490M -$33.58M
YoY Change -0.11% 45.55% 74.5%
INVESTING ACTIVITIES
Capital Expenditures -$700.0K -$900.0K $2.345M
YoY Change -22.22% 200.0% -65.87%
Acquisitions
YoY Change
Other Investing Activities -$770.0K -$500.0K $16.25M
YoY Change 54.0% -110.0% 118.71%
Cash From Investing Activities -$1.460M -$1.390M $13.91M
YoY Change 5.04% -129.57% 2397.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $31.63M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 33.49M 0.000 65.12M
YoY Change 35875.69%
NET CHANGE
Cash From Operating Activities -9.480M -9.490M -33.58M
Cash From Investing Activities -1.460M -1.390M 13.91M
Cash From Financing Activities 33.49M 0.000 65.12M
Net Change In Cash 22.55M -10.88M 45.44M
YoY Change -307.26% 497.8% -345.56%
FREE CASH FLOW
Cash From Operating Activities -$9.480M -$9.490M -$33.58M
Capital Expenditures -$700.0K -$900.0K $2.345M
Free Cash Flow -$8.780M -$8.590M -$35.93M
YoY Change 2.21% 38.1% 37.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70920693
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39403519
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020Q2 dei Entity Public Float
EntityPublicFloat
0
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001680048
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 us-gaap Tax Credit Carryforward Expiration Date
TaxCreditCarryforwardExpirationDate
2033-12-31
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-38191
CY2020 dei Entity Registrant Name
EntityRegistrantName
MUSTANG BIO, INC.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3828760
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
377 Plantation Street
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Worcester
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01605
CY2020 dei City Area Code
CityAreaCode
781
CY2020 dei Local Phone Number
LocalPhoneNumber
652-4500
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2020 dei Trading Symbol
TradingSymbol
MBIO
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020 mbio Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97804000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61413000
CY2020Q4 us-gaap Other Receivables
OtherReceivables
15000
CY2019Q4 us-gaap Other Receivables
OtherReceivables
19000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1715000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1631000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
99534000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
63063000
CY2020Q4 mbio Property Plant And Equipment Excluding Assets Under Construction
PropertyPlantAndEquipmentExcludingAssetsUnderConstruction
7529000
CY2019Q4 mbio Property Plant And Equipment Excluding Assets Under Construction
PropertyPlantAndEquipmentExcludingAssetsUnderConstruction
6779000
CY2020Q4 mbio Construction In Process Net
ConstructionInProcessNet
499000
CY2019Q4 mbio Construction In Process Net
ConstructionInProcessNet
1157000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1088000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1196000
CY2020Q4 us-gaap Assets
Assets
109900000
CY2019Q4 us-gaap Assets
Assets
73445000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8747000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5668000
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
490000
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
596000
CY2020Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
0
CY2019Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
1250000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
278000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
257000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9515000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7771000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
12179000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1950000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1843000
CY2020Q4 us-gaap Liabilities
Liabilities
11465000
CY2019Q4 us-gaap Liabilities
Liabilities
21793000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70920693
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39403519
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2020Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
2103122
CY2019Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
1206667
CY2020Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
7939000
CY2019Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
4923000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
275963000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
172184000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-185474000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125459000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
98435000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
51652000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109900000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73445000
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
37237000
CY2019 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
30042000
CY2020 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
10064000
CY2019 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
6273000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9505000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9570000
CY2020 us-gaap Operating Expenses
OperatingExpenses
56806000
CY2019 us-gaap Operating Expenses
OperatingExpenses
45885000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-56806000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-45885000
CY2020 us-gaap Interest Income Other
InterestIncomeOther
708000
CY2019 us-gaap Interest Income Other
InterestIncomeOther
1263000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
3917000
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
1767000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3209000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-504000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-60015000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-46389000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.14
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.29
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52588781
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36061811
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
36396000
CY2019 mbio Stock Issuance Common Stock Issuable During Period
StockIssuanceCommonStockIssuableDuringPeriod
4923000
CY2019 mbio Stock Issued During Value Issued For Venture Debt Financing Agreement
StockIssuedDuringValueIssuedForVentureDebtFinancingAgreement
375000
CY2019 mbio Warrants Issued During Period Value Issued For Horizon Note
WarrantsIssuedDuringPeriodValueIssuedForHorizonNote
888000
CY2019 mbio Stock Issued During Period Value At Marketing Offering
StockIssuedDuringPeriodValueAtMarketingOffering
21972000
CY2019 mbio Stock Issued During Period Value Equity Fee On At Market Offering
StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering
495000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29537000
CY2019 mbio Stock Issued During Period Value New Issues Equity Fee On Public Offering
StockIssuedDuringPeriodValueNewIssuesEquityFeeOnPublicOffering
791000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2664000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-46389000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
51652000
CY2020 mbio Stock Issuance Common Stock Issuable During Period
StockIssuanceCommonStockIssuableDuringPeriod
7577000
CY2020 mbio Stock Issued During Period Value At Marketing Offering
StockIssuedDuringPeriodValueAtMarketingOffering
58597000
CY2020 mbio Stock Issued During Period Value Equity Fee On At Market Offering
StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering
1514000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34842000
CY2020 mbio Stock Issued During Period Value New Issues Equity Fee On Public Offering
StockIssuedDuringPeriodValueNewIssuesEquityFeeOnPublicOffering
932000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
349000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2987000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-60015000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
98435000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-60015000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-46389000
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2321000
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
710000
CY2020 mbio Issuance Of Common Shares Equity Fee On At Market Offering
IssuanceOfCommonSharesEquityFeeOnAtMarketOffering
1514000
CY2019 mbio Issuance Of Common Shares Equity Fee On At Market Offering
IssuanceOfCommonSharesEquityFeeOnAtMarketOffering
495000
CY2020 mbio Issuance Of Common Shares Equity Fee On Public Offering
IssuanceOfCommonSharesEquityFeeOnPublicOffering
932000
CY2019 mbio Issuance Of Common Shares Equity Fee On Public Offering
IssuanceOfCommonSharesEquityFeeOnPublicOffering
791000
CY2020 mbio Issuance Of Common Shares Equity Fee On Venture Notes
IssuanceOfCommonSharesEquityFeeOnVentureNotes
0
CY2019 mbio Issuance Of Common Shares Equity Fee On Venture Notes
IssuanceOfCommonSharesEquityFeeOnVentureNotes
375000
CY2020 mbio Adjustment To Recognize Effect Of Research And Development Expense Attributable To Asset Acquired Via Stock Issuance
AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance
7577000
CY2019 mbio Adjustment To Recognize Effect Of Research And Development Expense Attributable To Asset Acquired Via Stock Issuance
AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance
4923000
CY2020 mbio Research And Development License In Accounts Payable And Accrued Expense
ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense
2487000
CY2019 mbio Research And Development License In Accounts Payable And Accrued Expense
ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense
1350000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2987000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
2664000
CY2020 us-gaap Depreciation
Depreciation
1677000
CY2019 us-gaap Depreciation
Depreciation
1258000
CY2020 mbio Operating Lease Right Of Use Assets Amortization
OperatingLeaseRightOfUseAssetsAmortization
108000
CY2019 mbio Operating Lease Right Of Use Assets Amortization
OperatingLeaseRightOfUseAssetsAmortization
110000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
84000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
558000
CY2020 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-4000
CY2019 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
19000
CY2020 mbio Increase Decrease In Accounts Payable And Accrued Expenses Excluding Amounts Due To Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties
3151000
CY2019 mbio Increase Decrease In Accounts Payable And Accrued Expenses Excluding Amounts Due To Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties
296000
CY2020 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-106000
CY2019 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
360000
CY2020 mbio Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-128000
CY2019 mbio Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-53000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37319000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33581000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
0
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
17604000
CY2020 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2487000
CY2019 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1350000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1925000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2345000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4412000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13909000
CY2020 mbio Proceeds From Horizon Notes
ProceedsFromHorizonNotes
0
CY2019 mbio Proceeds From Horizon Notes
ProceedsFromHorizonNotes
15000000
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2019 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1393000
CY2020 mbio Proceeds From Issuance Of Common Shares At Market Offering
ProceedsFromIssuanceOfCommonSharesAtMarketOffering
59805000
CY2019 mbio Proceeds From Issuance Of Common Shares At Market Offering
ProceedsFromIssuanceOfCommonSharesAtMarketOffering
22515000
CY2020 mbio Offering Costs For Issuance Of Common Shares At Market Offering
OfferingCostsForIssuanceOfCommonSharesAtMarketOffering
1124000
CY2019 mbio Offering Costs For Issuance Of Common Shares At Market Offering
OfferingCostsForIssuanceOfCommonSharesAtMarketOffering
543000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37230000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
31625000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2388000
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2088000
CY2020 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-15750000
CY2019 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
0
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
349000
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
78122000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65116000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
36391000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
45444000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62413000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16969000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98804000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62413000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
1593000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
1057000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
31000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
187000
CY2020 us-gaap Stock Issued1
StockIssued1
4923000
CY2019 us-gaap Stock Issued1
StockIssued1
2085000
CY2020 mbio Offering Costs For Issuance Of Common Shares At Market Offering In Accounts Payable And Accrued Expenses
OfferingCostsForIssuanceOfCommonSharesAtMarketOfferingInAccountsPayableAndAccruedExpenses
84000
CY2019 mbio Offering Costs For Issuance Of Common Shares At Market Offering In Accounts Payable And Accrued Expenses
OfferingCostsForIssuanceOfCommonSharesAtMarketOfferingInAccountsPayableAndAccruedExpenses
0
CY2020 mbio Issue Of Warrants
IssueOfWarrants
0
CY2019 mbio Issue Of Warrants
IssueOfWarrants
888000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-185500000
CY2020 mbio Number Of Subsidiaries
NumberOfSubsidiaries
0
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1000000.0
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1000000.0
CY2020 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2017Q4 mbio Lessee Operating Lease Total Base Rent Net Of Abatements
LesseeOperatingLeaseTotalBaseRentNetOfAbatements
3600000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8565018
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8308821
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
0
CY2019Q1 us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2016Q3 mbio Preferred Stock Voting Rights Multiplier
PreferredStockVotingRightsMultiplier
1.1
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
800000
CY2017Q4 mbio Lessee Security Deposit Upon Full Occupancy
LesseeSecurityDepositUponFullOccupancy
1300000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2200000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11595000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9826000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3567000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1890000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8028000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7936000
CY2020 us-gaap Depreciation
Depreciation
1700000
CY2019 us-gaap Depreciation
Depreciation
1300000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3518000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1877000
CY2020Q4 mbio Research And Development Current
ResearchAndDevelopmentCurrent
2862000
CY2019Q4 mbio Research And Development Current
ResearchAndDevelopmentCurrent
1760000
CY2020Q4 mbio Accrued Compensation Current
AccruedCompensationCurrent
2009000
CY2019Q4 mbio Accrued Compensation Current
AccruedCompensationCurrent
1496000
CY2020Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
358000
CY2019Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
535000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8747000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5668000
CY2017Q4 us-gaap Net Rentable Area
NetRentableArea
27043
CY2017Q4 mbio Lessee Operating Lease Total Abatements Over Lease Term
LesseeOperatingLeaseTotalAbatementsOverLeaseTerm
600000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1100000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
330000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
312000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
470000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
684000
CY2020 us-gaap Lease Cost
LeaseCost
800000
CY2019 us-gaap Lease Cost
LeaseCost
996000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
76000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
148000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y9M18D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
467000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
476000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
489000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
503000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
516000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
439000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2890000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
662000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2228000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
85000000
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
85000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
85000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.04
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.03
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
259144
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2987000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
2664000
CY2020 mbio Employee Stock Purchase Plan Predetermined Offering Period Lower Fair Market Value Percentage
EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage
0.85
CY2020 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
140856
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.16
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.15
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.01
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0
CY2020 mbio Effective Income Tax Rate Reconciliation Change In State Enacted Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent
0.01
CY2019 mbio Effective Income Tax Rate Reconciliation Change In State Enacted Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent
0.04
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.02
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.41
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.41
CY2020 mbio Effective Income Tax Rate Reconciliation Change In Federal Enacted Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent
0
CY2019 mbio Effective Income Tax Rate Reconciliation Change In Federal Enacted Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
45090000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27446000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
2444000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
2037000
CY2020Q4 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
59000
CY2019Q4 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
57000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
12804000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
9454000
CY2020Q4 mbio Deferred Tax Asset Operating Lease Liabilities
DeferredTaxAssetOperatingLeaseLiabilities
825000
CY2019Q4 mbio Deferred Tax Asset Operating Lease Liabilities
DeferredTaxAssetOperatingLeaseLiabilities
746000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
504000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
519000
CY2020Q4 mbio Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
7000
CY2019Q4 mbio Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
7000
CY2020Q4 mbio Deferred Tax Assets Tax Debt Issuance Costs
DeferredTaxAssetsTaxDebtIssuanceCosts
0
CY2019Q4 mbio Deferred Tax Assets Tax Debt Issuance Costs
DeferredTaxAssetsTaxDebtIssuanceCosts
21000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
5743000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2746000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
67476000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
43033000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
67073000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42608000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
403000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
425000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
403000
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
425000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
67100000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42600000
CY2020 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0

Files In Submission

Name View Source Status
0001558370-21-003433-index-headers.html Edgar Link pending
0001558370-21-003433-index.html Edgar Link pending
0001558370-21-003433.txt Edgar Link pending
0001558370-21-003433-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20201231.xsd Edgar Link pending
tmb-20201231x10k.htm Edgar Link pending
tmb-20201231x10k_htm.xml Edgar Link completed
tmb-20201231xex23d1.htm Edgar Link pending
tmb-20201231xex31d1.htm Edgar Link pending
tmb-20201231xex31d2.htm Edgar Link pending
tmb-20201231xex32d1.htm Edgar Link pending
tmb-20201231xex32d2.htm Edgar Link pending
tmb-20201231xex4d3.htm Edgar Link pending
tmb-20201231_cal.xml Edgar Link unprocessable
tmb-20201231_def.xml Edgar Link unprocessable
tmb-20201231_lab.xml Edgar Link unprocessable
tmb-20201231_pre.xml Edgar Link unprocessable